FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197500869> ?p ?o ?g. }

• W3197500869 abstract "Abstract Context On March 11, the World Health Organization (WHO) announced the current corona virus disease 2019 (COVID-19) outbreak as a pandemic. The first laboratory-confirmed case of COVID-19 in Austria was announced on February 27, 2020. Since then, the incidence of infection followed an exponential increase until a complete lockdown in March 2020. Thereafter easing of restrictions was gradually introduced and until mid-August daily infections remained mostly below 5 per 100.000 population. Objectives The aims of this study are to determine i) how many employees in Austrian trauma hospitals and rehabilitation facilities have virus specific IgG and IgM, and/or neutralizing antibodies against SARS-CoV-2, ii) how many are active virus carriers (symptomatic and asymptomatic) during the study, iii) the antibody decline in seropositive subjects over a period of around six months, and iv) the utility of rapid antibody tests for outpatient screening. Study Design Open uncontrolled observational cross-sectional study. Setting/Participants A total of 3301 employees in 11 Austrian trauma hospitals and rehabilitation facilities of the Austrian Social Insurance for Occupational Risks (AUVA) participated in the study. Study Interventions and Measures Rapid antibody tests for SARS-CoV-2 specific IgG and IgM antibodies, and RT-PCR tests based on oropharyngeal swab samples, as well as laboratory-based antibody tests using ELISA/PRNT were performed. The tests were conducted twice, with an interval of 42.4±7.7 (Min=30, Max=64) days. Additionally, participants filled out a questionnaire including questions related to personal health, traveling activities, living situation, as well as inquiries of symptoms and comorbidities. Antibody positive tested participants were re-tested with ELISA/PRNT tests at a third time point on average 188.0±12.8 days after their initial test. Results In our study cohort, only 27 out of 3301 participants (0.81%) had a positive antibody test at any time point during the study confirmed via neutralization test. Among participants who had positive test results in either of the antibody tests, 50.4% did not report any symptoms consistent with common manifestations of COVID-19 during the study period or within the preceding six weeks. In the group who tested positive during or prior to study inclusion the most common symptoms of an acute viral illness were rhinitis (21.9%), and loss of taste and olfactory sense (21.9%). The rapid antibody test was generally more sensitive based on serum (sensitivity=86.6%) as compared to whole blood (sensitivity=65.4). Concerning both ELISA tests overall the Roche test detected 24 (sensitivity=88.9%) and the Diasorin test 22 positive participants (sensitivity=81.5%). In participants with a positive PRNT, a significant decrease in PRNT concentration from 31.8±22.9 (Md=32.0) at T1 to 26.1±17.6 (Md=21.3) at T2 to 21.4±13.4 (Md=16.0) at T3 (χ 2 =23.848, df=2, p<0.001) was observed (χ 2 =23.848, df=2, p<0.001) – with an average time of 42.4±7.7 days between T1 and T2 and 146.9±13.8 days between T2 and T3. Conclusions During the study period (May 11 th – December 21 th ) only 0.81% were tested positive for antibodies in our study cohort. The antibody concentration decreases significantly over time with 14.8% (4 out of 27) losing detectable antibodies." @default.
• W3197500869 created "2021-09-13" @default.
• W3197500869 creator A5011313044 @default.
• W3197500869 creator A5015669479 @default.
• W3197500869 creator A5016011839 @default.
• W3197500869 creator A5017515539 @default.
• W3197500869 creator A5019790538 @default.
• W3197500869 creator A5025235335 @default.
• W3197500869 creator A5030343627 @default.
• W3197500869 creator A5033955260 @default.
• W3197500869 creator A5046156507 @default.
• W3197500869 creator A5065570484 @default.
• W3197500869 creator A5068178323 @default.
• W3197500869 creator A5070515045 @default.
• W3197500869 creator A5072608182 @default.
• W3197500869 creator A5073590053 @default.
• W3197500869 creator A5088733919 @default.
• W3197500869 creator A5090779295 @default.
• W3197500869 date "2021-02-03" @default.
• W3197500869 modified "2023-09-23" @default.
• W3197500869 title "Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel" @default.
• W3197500869 cites W2999304916 @default.
• W3197500869 cites W3001195213 @default.
• W3197500869 cites W3002539152 @default.
• W3197500869 cites W3004912618 @default.
• W3197500869 cites W3005995896 @default.
• W3197500869 cites W3006065484 @default.
• W3197500869 cites W3006110666 @default.
• W3197500869 cites W3006645647 @default.
• W3197500869 cites W3006961006 @default.
• W3197500869 cites W3007104924 @default.
• W3197500869 cites W3007940623 @default.
• W3197500869 cites W3008209068 @default.
• W3197500869 cites W3008627141 @default.
• W3197500869 cites W3008696669 @default.
• W3197500869 cites W3009607814 @default.
• W3197500869 cites W3009912996 @default.
• W3197500869 cites W3010522809 @default.
• W3197500869 cites W3010564092 @default.
• W3197500869 cites W3010781325 @default.
• W3197500869 cites W3011971686 @default.
• W3197500869 cites W3012540309 @default.
• W3197500869 cites W3012756997 @default.
• W3197500869 cites W3012846954 @default.
• W3197500869 cites W3013640245 @default.
• W3197500869 cites W3016611530 @default.
• W3197500869 cites W3024506939 @default.
• W3197500869 cites W3025045992 @default.
• W3197500869 cites W3025364618 @default.
• W3197500869 cites W3040552450 @default.
• W3197500869 cites W3082342835 @default.
• W3197500869 cites W3086919571 @default.
• W3197500869 cites W3165656738 @default.
• W3197500869 doi "https://doi.org/10.1101/2021.02.01.21250898" @default.
• W3197500869 hasPublicationYear "2021" @default.
• W3197500869 type Work @default.
• W3197500869 sameAs 3197500869 @default.
• W3197500869 citedByCount "0" @default.
• W3197500869 crossrefType "posted-content" @default.
• W3197500869 hasAuthorship W3197500869A5011313044 @default.
• W3197500869 hasAuthorship W3197500869A5015669479 @default.
• W3197500869 hasAuthorship W3197500869A5016011839 @default.
• W3197500869 hasAuthorship W3197500869A5017515539 @default.
• W3197500869 hasAuthorship W3197500869A5019790538 @default.
• W3197500869 hasAuthorship W3197500869A5025235335 @default.
• W3197500869 hasAuthorship W3197500869A5030343627 @default.
• W3197500869 hasAuthorship W3197500869A5033955260 @default.
• W3197500869 hasAuthorship W3197500869A5046156507 @default.
• W3197500869 hasAuthorship W3197500869A5065570484 @default.
• W3197500869 hasAuthorship W3197500869A5068178323 @default.
• W3197500869 hasAuthorship W3197500869A5070515045 @default.
• W3197500869 hasAuthorship W3197500869A5072608182 @default.
• W3197500869 hasAuthorship W3197500869A5073590053 @default.
• W3197500869 hasAuthorship W3197500869A5088733919 @default.
• W3197500869 hasAuthorship W3197500869A5090779295 @default.
• W3197500869 hasBestOaLocation W31975008691 @default.
• W3197500869 hasConcept C116675565 @default.
• W3197500869 hasConcept C126322002 @default.
• W3197500869 hasConcept C151730666 @default.
• W3197500869 hasConcept C159047783 @default.
• W3197500869 hasConcept C159654299 @default.
• W3197500869 hasConcept C187212893 @default.
• W3197500869 hasConcept C194828623 @default.
• W3197500869 hasConcept C203014093 @default.
• W3197500869 hasConcept C2777910003 @default.
• W3197500869 hasConcept C2778494684 @default.
• W3197500869 hasConcept C2779343474 @default.
• W3197500869 hasConcept C2908647359 @default.
• W3197500869 hasConcept C37701844 @default.
• W3197500869 hasConcept C45189115 @default.
• W3197500869 hasConcept C71924100 @default.
• W3197500869 hasConcept C86803240 @default.
• W3197500869 hasConcept C99454951 @default.
• W3197500869 hasConceptScore W3197500869C116675565 @default.
• W3197500869 hasConceptScore W3197500869C126322002 @default.
• W3197500869 hasConceptScore W3197500869C151730666 @default.
• W3197500869 hasConceptScore W3197500869C159047783 @default.
• W3197500869 hasConceptScore W3197500869C159654299 @default.
• W3197500869 hasConceptScore W3197500869C187212893 @default.
• W3197500869 hasConceptScore W3197500869C194828623 @default.

• next